46LOW

IPD

IMPEDIMED FPO [IPD]
ImpediMed Limited, a medical technology company, develops, manufactures, and sells bioimpedance spectroscopy (BIS) technology medical devices and software services in Australia, Europe, the United States, and internationally. The company offers SOZO, a noninvasive BIS device for the clinical assessment of lymphedema, which uses bioimpedance measurements to assess fluid levels and tissue composition; L-Dex analysis for lymphedema; BodyComp Analysis, a point-of-care body composition analysis; and HF-Dex analysis for point-of-care heart failure fluid assessment. It also provides SFB7, a single-channel, tetrapolar BIS device to analyze body composition in healthy individuals; and ImpediVET, a single-channel, tetrapolar (BIS) device that measures fluid status and tissue composition for veterinary applications. ImpediMed Limited was incorporated in 1999 and is headquartered in Carlsbad, California with additional office in Lindfield, Australia.
Healthcare · ASX Small Cap
$0.0150 +0.0%

Updated 26 Mar 2026 · Scores refresh every scan

Score Breakdown

Technical52
Catalyst50
Sentiment50
Fundamental90
Momentum39
Risk Gate27
Get alerts when IPD's score changes
Free watchlist with daily scans for 2,200+ ASX stocks
Track IPD — Free

Active Signals

Bullish Signals

  • RSI drifting toward oversold territory — worth watching
  • Stochastic is deep in oversold territory — bounce conditions forming
  • Sitting near support — this level has held before and could attract buyers again
  • Drifting lower — down 6.3% over the last 5 days
  • Volatility is contracting — like a spring being compressed, breakouts often follow
  • Adequate cash runway (5 quarters)
  • Low P/S ratio (2.1x)
  • Strong revenue growth (+25%)
  • EPS estimates revised upward (+10pts)
  • Near 52-week low (0% of range)
  • Small-cap ($20-100M)
  • CANSLIM I: Institutional ownership (15%)
  • Turned profitable (NPAT positive from results)
  • Sentiment is mixed — no strong consensus either way
  • Altman Z-Score distress zone (0.34 < 1.81, low-confidence approx)
  • Penny stock risk ($0.015)
  • RBA hiking (-3pts)

Risk Signals

  • Trading below both moving averages — the trend is working against this one
  • Below the 200-day average — the long-term trend is still working against it
  • Piotroski F-Score weak (3/9, low-confidence approx)
  • Deeply negative margins (-171%)
  • Not enough chatter to gauge sentiment — defaulting to neutral
  • Long-term momentum is negative — down 40% over the past year
  • The bigger volume days are the down days — volume-weighted momentum is negative (-8.54%/day)
  • Overseas neutral (-2pts, S&P500 neutral, VIX 25)
Ask Scout AI about IPD
"What's driving IPD's score?" "How does IPD compare to peers?" "Key risks for IPD?"
3 free messages/day · Unlimited with Pro

Recent Catalysts

LOW FY26 H1 Results Investor Presentation
NONE FY26 Half Year Financial Results
NONE Appendix 4D and Interim Financial Report
NONE Initial Director's Interest Notice - Mr Erik Anderson

Recent ASX Announcements

2026-03-02 FY26 H1 Results Investor Presentation
2026-02-25 FY26 Half Year Financial Results PRICE SENSITIVE
2026-02-25 Appendix 4D and Interim Financial Report PRICE SENSITIVE
2026-02-25 Initial Director's Interest Notice - Mr Erik Anderson
2026-02-25 Appointment of Independent Non-executive Director

Key Metrics

$30.6M
Market Cap
2.6M
Avg Volume
0.7x
Vol Ratio
$0.01 — $0.06
52-Week Range
0.6%
Short Interest
N/A
Cash Runway
-117.9%
ROE
-171.3%
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandneutralFloat: 89%
LLeader vs LaggardlaggardRS: -13
IInstitutional SponsorshippassInst: 15%
MMarket DirectionneutralNeutral

Sector: Healthcare

Ranked #61 of 117 · Sector avg: 46

View all Healthcare signals →
Related Tickers
ATX 59PNV 56IMM 55EYE 55AHC 55
Compare:IPD vs ATXIPD vs PNVIPD vs IMM
Scout Pro — Deeper Analysis for IPD
Try Pro free for 30 days
Share this analysis

Track IPD and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and conviction scoring for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required